Dr Duane J Gubler | Emeritus Professor, Programme in Emerging Infectious Diseases
Duke-NUS Graduate Medical School

Dr Duane J Gubler, Emeritus Professor, Programme in Emerging Infectious Diseases, Duke-NUS Graduate Medical School

Dr Duane J Gubler, ScD, FAAAS, FIDSA, FASTMH, is Emeritus Professor and founding director, Signature Research Program in Emerging Infectious Diseases at the Duke-NUS Medical School, Singapore. He is Adjunct Professor in his alma mater, Johns Hopkins Bloomberg School of Public Health, the Duke University School of Medicine and Duke Global Health Institute. He has spent his entire career working on tropical infectious diseases with an emphasis on dengue and other Aedes-transmitted diseases. He has extensive field experience in Asia, the Pacific, tropical America and Africa, and has published extensively on all aspects of dengue and other vector-borne infectious diseases, with over 350 publications and 2 books to his credit. Prof Gubler was founding Chief of the Dengue Branch, United States Centers for Disease Control and Prevention (CDC) in Puerto Rico for 9 years, Director of the Division of Vector-Borne Infectious Diseases, CDC in Fort Collins, Colorado for 15 years and Chair, Department of Tropical Medicine, Medical Microbiology and Pharmacology, University of Hawaii School of Medicine, in Honolulu for 5 years. He has and continues to serve on numerous WHO, national and international committees and study groups, and on the Scientific Advisory Boards of a number of companies and institutions. Prof Gubler was founding Chair, Board of Councillors, Pediatric Dengue Vaccine Initiative in Seoul, Korea, founding Chair, Partnership for Dengue Control in Lyon, France, and the Global Dengue and Aedes-transmitted Diseases Consortium in Seoul, Korea, for which he currently serves as Chairman. Prof Gubler is a Fellow, Infectious Disease Society of America, Fellow, American Association for the Advancement of Science, and Fellow and Past President of the American Society of Tropical Medicine and Hygiene.


DC Co-conference Day 2 April 4 @ 11:40

Can we use moderately effective vaccines for safe public use? Using Dengue as an example

back to speakers